Effect of the beta-adrenergic agonist L644,969 on muscle growth, endogenous proteinase activities, and postmortem proteolysis in wether lambs.
To examine the effect of a beta-adrenergic agonist (BAA) on muscle growth, proteinase activities, and postmortem proteolysis, 16 wether lambs were randomly assigned to receive 0 or 4 ppm of L644,969 in a completely mixed high-concentrate diet for 6 wk. Weight of the biceps femoris was 18.6% heavier in treated lambs. At 0 h after slaughter, treated lambs had higher cathepsin B (35.6%), cathepsins B + L (19.1%), calpastatin (62.8%), and m-calpain (24.6%) than control lambs, but both groups had similar mu-calpain activities. In both longissimus and biceps femoris muscles, treated lambs had higher protein and RNA and lower DNA concentrations. However, total DNA was not affected, indicating that the increase in muscle mass was probably due to muscle hypertrophy rather than to hyperplasia. The pattern of postmortem proteolysis was significantly altered by BAA feeding. In treated lambs, postmortem storage had no effect on the myofibril fragmentation index and degradation of desmin and troponin-T. These results indicate that the ability of the muscle to undergo postmortem proteolysis has been dramatically reduced with BAA feeding. Similar proteolytic systems are thought to be involved in antemortem and postmortem degradation of myofibrillar proteins, so BAA-mediated protein accretion is probably due, at least in part, to reduced protein degradation. To examine whether protein synthesis was altered with BAA feeding, the level of skeletal muscle alpha-actin mRNA was quantified. Longissimus muscle alpha-actin mRNA abundance was 30% greater in BAA-fed lambs. Collectively, these results indicate that dietary administration of BAA increases muscle mass through hypertrophy and that the increase in muscle protein accretion is due to reduced degradation and possibly to increased synthesis of muscle proteins.
Koohmaraie
M
M
Roman L. Hruska U.S. Meat Anim. Res. Center, U.S. Department of Agriculture, Clay Center, NE 68933.
Shackelford
S D
SD
Muggli-Cockett
N E
NE
Stone
R T
RT
D000199:Actins / Q000235:genetics; D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000818:Animals; D002135:Calcium-Binding Proteins / Q000032:analysis; D002154:Calpain / Q000032:analysis / Q000037:antagonists & inhibitors; D002403:Cathepsins / Q000032:analysis / Q000037:antagonists & inhibitors; D004247:DNA / Q000032:analysis; D010450:Endopeptidases / Q000187:drug effects* / Q000378:metabolism; D006984:Hypertrophy; D016018:Least-Squares Analysis; D008297:Male; D008460:Meat / Q000592:standards; D024510:Muscle Development; D009124:Muscle Proteins / Q000032:analysis / Q000378:metabolism; D009132:Muscles / Q000187:drug effects*; D011180:Postmortem Changes; D011725:Pyridines / Q000494:pharmacology*; D012313:RNA / Q000032:analysis; D012333:RNA, Messenger / Q000032:analysis; D011897:Random Allocation; D012756:Sheep / Q000254:growth & development* / Q000378:metabolism; D015430:Weight Gain / Q000187:drug effects
D000199:Actins; D000318:Adrenergic beta-Agonists; D002135:Calcium-Binding Proteins; D009124:Muscle Proteins; D011725:Pyridines; D012333:RNA, Messenger; C061557:6-amino-alpha-(((1-methyl-3-phenylpropyl)amino)methyl)-3-pyridine methanol; D012313:RNA; C033668:calpastatin; D004247:DNA; D002403:Cathepsins; D010450:Endopeptidases; D002154:Calpain